Royalty Pharma PLC
NASDAQ:RPRX

Watchlist Manager
Royalty Pharma PLC Logo
Royalty Pharma PLC
NASDAQ:RPRX
Watchlist
Price: 38.26 USD 0.45%
Market Cap: 22.1B USD

Intrinsic Value

The intrinsic value of one RPRX stock under the Base Case scenario is 64.62 USD. Compared to the current market price of 38.26 USD, Royalty Pharma PLC is Undervalued by 41%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RPRX Intrinsic Value
64.62 USD
Undervaluation 41%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Royalty Pharma PLC

What is Valuation History?
Ask AI Assistant
What other research platforms think about RPRX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is RPRX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Royalty Pharma PLC.

Explain Valuation
Compare RPRX to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Royalty Pharma’s core revenue streams are highly exposed to patent cliffs on its top-selling therapies, creating potential for steep revenue declines if pipeline replacements fail to materialize in time.

Increasing competition from rival royalty aggregators and private equity firms could drive up the cost of acquiring new royalty streams, limiting Royalty Pharma’s ability to secure favorable deals.

Regulatory setbacks—such as unexpectedly negative clinical trial results or pricing pressure for key drugs—could reduce the attractiveness of the underlying royalty streams and weaken long-term returns.

Bull Theses

Royalty Pharma’s diversified portfolio of royalties across multiple blockbuster therapies shields it from the volatility typically associated with single-drug exposure, supporting robust cash flows.

The company’s strong track record of securing royalty deals with leading biopharma innovators positions it as a partner of choice in the industry, enabling it to access lucrative late-stage pipelines.

Its ability to selectively deploy capital into promising clinical programs allows Royalty Pharma to grow royalties and expand its pipeline without the heavy R&D costs that conventional pharma players must shoulder.

Show More Less
How do you feel about RPRX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Royalty Pharma PLC

Current Assets 1.8B
Cash & Short-Term Investments 1.8B
Receivables 28.9m
Other Current Assets 5.5m
Non-Current Assets 17.5B
Long-Term Investments 16.5B
PP&E 19.8m
Intangibles 924.6m
Other Non-Current Assets 66.8m
Current Liabilities 530.8m
Accounts Payable 41.4m
Accrued Liabilities 29m
Other Current Liabilities 460.3m
Non-Current Liabilities 12.4B
Long-Term Debt 8.6B
Other Non-Current Liabilities 3.8B
Efficiency

Free Cash Flow Analysis
Royalty Pharma PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Royalty Pharma PLC

Revenue
2.3B USD
Operating Expenses
-817.2m USD
Operating Income
1.5B USD
Other Expenses
-767.7m USD
Net Income
765m USD
Fundamental Scores

RPRX Profitability Score
Profitability Due Diligence

Royalty Pharma PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

Exceptional Operating Margin
Strong 3Y Average Operating Margin
Exceptional Net Margin
Operating Margin is Increasing
57/100
Profitability
Score

Royalty Pharma PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

RPRX Solvency Score
Solvency Due Diligence

Royalty Pharma PLC's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Average D/E
Positive Net Debt
36/100
Solvency
Score

Royalty Pharma PLC's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RPRX Price Targets Summary
Royalty Pharma PLC

Wall Street analysts forecast RPRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RPRX is 46 USD with a low forecast of 35.02 USD and a high forecast of 58.8 USD.

Lowest
Price Target
35.02 USD
8% Downside
Average
Price Target
46 USD
20% Upside
Highest
Price Target
58.8 USD
54% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for RPRX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

RPRX Insider Trading
Buy and sell transactions by insiders

RPRX News

Other Videos
What is the Intrinsic Value of one RPRX stock?

The intrinsic value of one RPRX stock under the Base Case scenario is 64.62 USD.

Is RPRX stock undervalued or overvalued?

Compared to the current market price of 38.26 USD, Royalty Pharma PLC is Undervalued by 41%.

Back to Top